Stockscreener 앱 받기
2.77
9.77%
-0.30
시간 외 거래:
2.86
0.09
+3.25%
전일 마감가:
$3.07
열려 있는:
$3.04
하루 거래량:
476.21K
Relative Volume:
1.45
시가총액:
$155.59M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-0.8946
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
-13.17%
1개월 성능:
+8.63%
6개월 성능:
-25.94%
1년 성능:
-64.53%
1일 변동 폭
$2.755
$3.04
1주일 범위
$2.755
$3.75
52주 변동 폭
$1.78
$11.40
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.77 | 155.59M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineKYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $18.50 Average Target Price from Analysts - MarketBeat
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - marketscreener.com
3 Promising Penny Stocks With Market Caps Over $100M - Yahoo Finance
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Sees Large Increase in Short Interest - MarketBeat
Lead Plaintiff Appointed in Kyverna Class Action — Here’s How You Can Recover Your Losses - TradingView
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLC - MarketBeat
Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 4,990 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Ameriprise Financial Inc. Raises Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts - MSN
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
BNP Paribas Financial Markets Purchases 17,786 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Northern Trust Corp Purchases 61,757 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Buy" at HC Wainwright - MarketBeat
Kyverna Therapeutics to Present at the Jefferies Global Healthca - GuruFocus
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PR Newswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to “Buy” at HC Wainwright - Defense World
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright - marketscreener.com
HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX) - Nasdaq
Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position - TipRanks
HC Wainwright Upgrades Kyverna Therapeutics to Buy From Neutral, Adjusts Price Target to $5 From $4 - marketscreener.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
HC Wainwright Issues Pessimistic Estimate for KYTX Earnings - MarketBeat
Analysts Offer Predictions for KYTX Q1 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Outlook for KYTX Earnings - Defense World
Analysts Issue Forecasts for KYTX Q1 Earnings - Defense World
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Jacobs Levy Equity Management Inc. Buys 442,090 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Sphera Funds Management LTD. - MarketBeat
Integral Health Asset Management LLC Purchases 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Leerink Partnrs Has Positive Outlook of KYTX Q2 Earnings - Defense World
Stifel Financial Corp Buys New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO - Bloomberg Law News
Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients - Myasthenia Gravis News
With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors - Yahoo Finance
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):